x min read

Here's Our Take On Mymetics Corp (OTCMKTS:MYMX)

Here's Our Take On Mymetics Corp (OTCMKTS:MYMX)
Written by
Jarrod Wesson
Published on
July 22, 2017
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Share price of Mymetics Corp (OTCMKTS:MYMX), a biotechnology firm, jumped recently on no news. In just a few days, the share price went from trading at $0.02 to touch the level of $0.08. Later on, it declined a bit, as market participants booked profits. Have a look at the recent price action:SourceThe fact that the company did not release anything to justify the share price move interested the team. As we usually do, we reviewed the previous press releases to understand what can be going on. In this article, we will put out our conclusions.BusinessSourceMYMX is a Swiss based biotechnology firm founded in 1990s. The company is well-known for its R&D on vaccines. The following is a list of its candidates under development:

Vaccine

Pre-Clinical

Phase I

HIV-1

X

RSV

On hold

HSV

On hold

Malaria

X

Influenza

X

Chikungunya

X

SourceIn this piece, we will focus on the candidate for the HIV-1. Its study has been operative since 2005. Mymetics Corp. achieved its first significant breakthrough in 2008. Later on, it achieved another notable development in 2014 after Mymetics Corporation and Texas Biomed research institution combined forces to create the vaccine.On April 11, 2016, Mymetics Corporation reported that one of its HIV vaccine candidates exhibited a significant improvement. Mymetics initially conducted the test on thirty-six female monkeys. The study allocated three different groups with twelve monkeys per group. The study was led by Dr. Ruth Ruprecht, a leading scientist in HIV vaccine and the Director of the Texas Biomed AIDS research program, which is operating under the Bill & Melinda Gates Foundation. During the initial studies, the vaccine developed by Mymetics exhibited a significant 87% delay in the spreading of infection among the control group of the study. As the next phase of the study, Mymetics Corp. increased the dose by 50% to see the impact caused by the vaccines on their immune system. However, the vaccine did not show any notable improvements.

We are encouraged by the initial strong protection provided by the vaccine candidate, which is in line with the results from an earlier primate study performed in China that we were asked to repeat. The fact that the vaccine-induced immune defenses were eventually overcome requires a careful analysis to understand the mechanisms of the initial vaccine action and to learn what other immune defenses can be enlisted to yield even more potent antiviral action Source

In September 2016, the press release by Mymetics Corporation reported that the collaboration between Mymetics Corporation and Texas Biomed research institution would continue, as they aim at developing first and second line of defense against the HIV infection. The first line of defense is through mucosal protection, while the second line of defense will be through the blood antibodies. Both Mymetics Corporation and Texas Biomed research will move on to the next phase of animal testing. The press report also stated that research would be funded by the Bill & Melinda Gates Foundation.On December 1, 2016, the Press release by Mymetics Corporation announced that it would combine forces with Sanofi; a leading France based pharmaceutical firm. Mymetics Corp announced that it would conduct research on the influenza vaccines that will help in provoking the immune response in the body of animals. The vaccines are based on the virosome technology developed by Mymetics in pre-clinical settings. Ronald Kempers, CEO of Mymetics, celebrated the news with the following words:

"We look forward to show that our proprietary virosome technology and more than 30 years of virosome vaccines expertise can make a valuable difference in improving the effectiveness and cost competitiveness of influenza vaccines." Source

Sanofi The announcement of the collaboration with Sanofi brought a lot of prestige to the company, as it is one of the biggest pharmaceutical firms in the world. This new partner is exactly what MYMX needed. It can provide financing to the company. Additionally, even if it will only be collaborating on influenza vaccines, the agreement is expected to open the door to new agreements for other candidates of MYMX. Futhermore, other bigger companies may be willing to work with the company now. The market celebrated this news by pushing up the share price from $0.01 to $0.08 in December. The new share price jump seen in July is almost equivalently important. Thus, it is not quite illogical to think that something regarding its work with Sanofi may be going on.Furthermore, we were able to gather the following on Yahoo Finance :

"Tomorrow - Sanofi and partners speak at the UN on progress being made in tropical diseases. No mention of specific partners but have to guess mymetics will be mentioned. Got this from twitter feed off Sanofi group media page on their website." Source

Source: SanofiMarket participants that declared big stakesWe are not the only one analyzing the news of MYMX. The following market participants declared equity stakes in the company.

HolderSharesDate Reported% OutValueIAT Reinsurance Co Ltd2,186,473Mar 30, 20170.72%48,102Tanaka Capital Management, Inc.167,649Mar 30, 20170.06%3,688SourceThe following mutual fund also bought a stake.

HolderSharesDate Reported% OutValueTanaka Growth Fund113,377Nov 29, 20160.04%1,133

Source

ConclusionWe reviewed the recent announcements to explain the unusual activity registered by MYMX. The company did not put out that it would be releasing any valuable data in July, 2017. Thus, we believe that the reason to explain the move should be searched outside the company. In our opinion, the fact that Sanofi is working with MYMX and it announced that it would be present at the UN's forum dedicated to neglected tropical diseases was significant. MYMX's R&D work is focused on Malaria, Chikungunya and Influenza, which are tropical diseases. Hence, some market participants may have expected some comments about MYMX. If something was said, we expect the company to communicate it soon. So, we need to be alert. In addition, the fact that some market participants bought large stakes in the company is another interesting fact. They may have acquired more shares and moved the market. To sum up, MYMX seems to be in play, try to follow it closely.We will be updating our subscribers as soon as we know more. For the latest updates on MYMX, sign up below!Image courtesy of Colleen Pence via FlickrDisclosure: We have no position in MYMX and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.